BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kleiner G, Fernandez HH, Chou KL, Fasano A, Duque KR, Hengartner D, Law A, Margolius A, Poon Y, Sáenz Farret M, Saleh P, Vizcarra JA, Stebbins GT, Espay AJ; PSG NoMoFA Study Group. Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire. Mov Disord 2021;36:1392-400. [DOI: 10.1002/mds.28507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tsuboi T, Satake Y, Hiraga K, Yokoi K, Hattori M, Suzuki M, Hara K, Ramirez-Zamora A, Okun MS, Katsuno M. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review. NPJ Parkinsons Dis 2022;8:75. [PMID: 35697709 DOI: 10.1038/s41531-022-00339-2] [Reference Citation Analysis]
2 Muhammad F, Liu Y, Zhou Y, Yang H, Li H. Antioxidative role of Traditional Chinese Medicine in Parkinson's disease. J Ethnopharmacol 2022;285:114821. [PMID: 34838943 DOI: 10.1016/j.jep.2021.114821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Gupta S, Shukla S. Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment. Current Research in Behavioral Sciences 2021;2:100049. [DOI: 10.1016/j.crbeha.2021.100049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Faggianelli F Jr, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T; NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson's disease. Rev Neurol (Paris) 2021:S0035-3787(21)00671-8. [PMID: 34565624 DOI: 10.1016/j.neurol.2021.06.013] [Reference Citation Analysis]
5 Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. Expert Rev Neurother 2021;21:1019-33. [PMID: 34525893 DOI: 10.1080/14737175.2021.1968298] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
6 Ghoraani B, Galvin JE, Jimenez-Shahed J. Response to "Comment on: "Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information". Parkinsonism Relat Disord 2021;86:134. [PMID: 33896690 DOI: 10.1016/j.parkreldis.2021.04.015] [Reference Citation Analysis]